🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

7,888 results for “1” Clear

  1. Safety, Tolerability and Pharmacokinetic Profile of TPT0301 in Healthy Volunteers

    Alphapharm Pty Ltd

    adjunctive neuropathic pain

    phase 1 other active

    1 trial

  2. Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AB-101 Following Oral Administration in Healthy and Chronic Hepatitis B Subjects

    Arbutus Biopharma Corp

    Chronic hepatitis B virus Infection

    phase 1 other active

    1 trial

  3. Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NBI-1076986 in Healthy Adults.

    NEUROCRINE BIOSCIENCES INC

    Movement disorders

    phase 1 other active

    1 trial

  4. Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NBI-1117570 in Healthy Adults

    NEUROCRINE BIOSCIENCES INC

    Neurological and neuropsychiatric conditions

    phase 1 other active

    1 trial

  5. Safety, pharmacokinetics and pharmacodynamics study of Leucettinib-21 in healthy subjects, Down Syndrom and Alzheimer patients

    Lacuna Pharma Pty Ltd

    A Phase 1, Randomized, Double-Blind, Placebo-Controlled, First in Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Ascending Doses and Food Effect of Leucettinib-21 in Healthy Male Subjects, followed by an open single dose of Leucettinib-21 in Down Syndrome individuals, and patients with Alzheimer’s disease

    phase 1 other active

    1 trial

  6. Safety, tolerability, pharmacokinetics, and pharmacodynamics of intravenous and subcutaneous multiple rising doses of BI 765250 versus placebo in trial participants with moderate to severe plaque psoriasis (double-blind, randomised, placebo-controlled, parallel-group design)

    Boehringer Ingelheim

    Plaque psoriasis

    phase 1 other active

    1 trial

  7. Semaglutide Extended-release for Injectable Suspension, 1 mg

    BRIGHT MINDS BIOSCIENCES INC.

    Diabetes Mellitus, Type 2

    phase 1 small molecule active

    1 trial

  8. Short-Term Linvoseltamab Treatment, on Top of Chronic Dupilumab Treatment, for Adults with Severe Immunoglobulin E (IgE)-Mediated Food Allergy

    Lacuna Pharma Pty Ltd

    Severe IgE-mediated food allergy

    phase 1 other active

    1 trial

  9. Single Ascending Dose of SAB-176

    SAB Biotherapeutics

    PHA1A

    phase 1 small molecule active

    1 trial

  10. Single Dose Pharmacokinetics and Relative Bioavailability of Sayana Press via Upper Arm Injection Relative to Anterior Thigh and Abdomen

    Pfizer Australia Pty Ltd

    long-term female contraception

    phase 1 other active

    1 trial

  11. Single FT1050 treated UCB unit

    Zafatek

    Non-Hodgkin's Lymphoma (NHL)

    phase 1 mab completed

    1 trial

  12. Single dose oral bioequivalence study of Cladribine 10 mg Tablets and Mavenclad® 10 mg tablets (Cladribine) in healthy adult human subjects under fed conditions

    Lacuna Pharma Pty Ltd

    No therapeutic indication in the current trial with healthy volunteers.

    phase 1 other active

    1 trial

  13. Single dose, open-label, laboratory blinded, randomized, 2-treatment, 2-period, 2-sequence, crossover, pivotal study to assess the comparative bioavailability of Test Product Dapagliflozin/metformin hydrochloride 5 mg/1000 mg film-coated tablets to Reference Product Xigduo 5 mg/1000 mg film-coated tablets in healthy adult male and female subjects under fed conditions.

    Laboratorios Tillomed Spain S.L.U

    Bioavailability study in healthy volunteers under fed conditions.

    phase 1 other active

    1 trial

  14. Single dose, open-label, laboratory blinded, randomized, 2-treatment, 2-period, 2-sequence, crossover, pivotal study to assess the relative bioavailability of Test Product Naproxen sodium 660 mg modified release tablets to Reference Product Actromadol 660 mg Modified-Release tablets in healthy adult male and female subjects under fed conditions.

    Laboratorios Tillomed Spain S.L.U

    No medical condition

    phase 1 other active

    1 trial

  15. Single dose, open-label, laboratory blinded, randomized, 2-treatment, 2-period, 2-sequence, crossover, pivotal study to assess the relative bioavailability of Test Product Naproxen sodium 660 mg modified release tablets to Reference Product Actromadol 660 mg Modified-Release tablets in healthy adult male and female subjects under fasting conditions.s.

    Laboratorios Tillomed Spain S.L.U

    Bioavailability study in healthy volunteers under fasting conditions.

    phase 1 other active

    1 trial

  16. Single-Ascending Doses of 2-Methoxyestradiol in Healthy Non-Pregnant Female Subjects.

    Laboratorios Tillomed Spain S.L.U

    No medical condition.

    phase 1 other active

    1 trial

  17. Single-Dose Study in Healthy Participants to Compare the Bioavailability of One Film-Coated Mini-Tablet of Indapamide SR 1.5 mg versus One Film-Coated Tablet of Indapamide IR 2.5 mg Under Fasting Conditions, and to Compare the Bioavailability of One Film-Coated Mini-Tablet of Indapamide SR 1.5 mg Under Fasting versus Fed Conditions.

    The George Institute

    No medical condition.

    phase 1 other active

    1 trial

  18. Single-center, single-dose, open-label, laboratory-blinded, randomized, two-treatment, two-period bioequivalence (BE) study comparing the Test Product Apixaban 5 mg film-coated tablets (MEDITOP) with the Reference Product Eliquis 5 mg film-coated tablets (Bristol-Myers Squibb/Pfizer) under fasting conditions.

    Pari Pharma GmbH

    Comparative bioequivalence study in healthy volunteers under fasting conditions.

    phase 1 other active

    1 trial

  19. Sinovac PCV24 formulation 1

    Sinovac Research and Development Co.,

    Pneumococcal Infectious Disease

    phase 1 mab completed

    2 trials

  20. Solriamfetol 150 mg Oral Tablet

    Axsome Therapeutics

    Narcolepsy

    phase 1 small molecule completed

    1 trial

  21. Sotrovimab

    Vir Biotechnology

    COVID-19 Infection

    phase 1 mab terminated

    1 trial

  22. Spinraza 12 mg solution for injection

    Biogen

    Spinal Muscular Atrophy

    phase 1 small molecule active

    1 trial

  23. Study of ARO-ATXN2 Injection in Adults With Spinocerebellar Ataxia Type 2

    Arrowhead Pharmaceuticals Ireland Limited

    spinocerebellar ataxia type 2

    phase 1 other active

    1 trial

  24. Study of BGB-11417 in Patients with Mature B Cell Malignancies

    BEONE MEDICINES AUS PTY LTD

    Mature B Cell Malignancies

    phase 1 other active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources